Febuxostat
- Generic Name
- Febuxostat
- Brand Names
- Adenuric, Uloric, Febuxostat Viatris (previously Febuxostat Mylan), Febuxostat Krka
- Drug Type
- Small Molecule
- Chemical Formula
- C16H16N2O3S
- CAS Number
- 144060-53-7
- Unique Ingredient Identifier
- 101V0R1N2E
- Background
Febuxostat is a non-purine xanthine oxidase (XO) inhibitor. In early 2008, febuxostat was granted marketing authorization by the European Commission for the treatment of chronic hyperuricemia and gout. In the following year, the FDA for approved febuxostat for use in the chronic management of hyperuricemia in adult patients with gout who have an inadequate r...
- Indication
Febuxostat is indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. It is not recommended for the treatment of asymptomatic hyperuricemia or secondary hyperuricem...
- Associated Conditions
- Chronic, symptomatic Hyperuricemia
- Associated Therapies
- -
The Effect of Uric Acid Lowering in Type 1 Diabetes
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 73
- Registration Number
- NCT02344602
- Locations
- 🇨🇦
Renal Physiology Laboratory, University Health Network, Toronto, Ontario, Canada
Compare the Renal Protective Effects of Febuxostat and Benzbromarone
- Conditions
- Interventions
- First Posted Date
- 2015-01-14
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Shanghai 10th People's Hospital
- Target Recruit Count
- 160
- Registration Number
- NCT02338323
- Locations
- 🇨🇳
Department of Nephrology & Rheumatology, Shanghai Tenth People's Hospital, Shanghai, Shanghai, China
A PD/Safety Study of RDEA3170 in Combination With Febuxostat for Treating Gout or Asymptomatic Hyperuricemia Patients
- Conditions
- Interventions
- First Posted Date
- 2014-12-17
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 110
- Registration Number
- NCT02317861
- Locations
- 🇯🇵
Research Site, Fukuoka-shi, Japan
A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
- First Posted Date
- 2014-11-11
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- TWi Biotechnology, Inc.
- Target Recruit Count
- 127
- Registration Number
- NCT02287818
- Locations
- 🇨🇳
Taipei Veteran General Hospital (TVGH), Taipei, Taiwan
the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia
- First Posted Date
- 2014-10-31
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Yokohama City University Medical Center
- Target Recruit Count
- 1
- Registration Number
- NCT02279342
- Locations
- 🇯🇵
Yokohama City University Medical Center, Yokohama, Kanagawa, Japan
Evaluate the PK, PD, and Safety of Arhalofenate in Combination With Febuxostat for Hyperuricemia in Patients With Gout
- Conditions
- Interventions
- First Posted Date
- 2014-09-30
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- CymaBay Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT02252835
- Locations
- 🇺🇸
Vince & Associates Clinical Research, Overland Park, Kansas, United States
Safety and Efficacy of Oral Febuxostat in Subjects With Gout
- First Posted Date
- 2014-03-10
- Last Posted Date
- 2016-02-03
- Lead Sponsor
- Xijing Hospital
- Target Recruit Count
- 504
- Registration Number
- NCT02082769
Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels
- First Posted Date
- 2014-02-12
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 96
- Registration Number
- NCT02060552
- Locations
- 🇨🇳
Yikai YU, Wuhan, Hubei, China
Febuxostat for Cerebral and caRdiorenovascular Events prEvEntion stuDy
- First Posted Date
- 2013-11-15
- Last Posted Date
- 2016-08-26
- Lead Sponsor
- Freed Study Group
- Target Recruit Count
- 1000
- Registration Number
- NCT01984749
- Locations
- 🇯🇵
Hanaoka IC Clinic, Buzen, Fukuoka, Japan
🇯🇵Medical Cooperation Toseikai Goto Clinic, Kitakyushu, Fukuoka, Japan
🇯🇵Yokohama Sotetsu bldg Clinic of Internal Medicine, Yokohama, Kanagawa, Japan
Lesinurad and Febuxostat Combination Extension Study in Gout
- First Posted Date
- 2013-03-11
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Ardea Biosciences, Inc.
- Target Recruit Count
- 196
- Registration Number
- NCT01808144
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.